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Abstract
Background: The objective of this study was to assess temporal changes in incidence and short term mortality of
Staphylococcus aureus bacteraemia (SAB) from 1995 through 2008.
Methods: The study was conducted as a nation-wide observational cohort study with matched population
controls. The setting was hospitalized patients in Denmark 1995-2008. Uni- and multivariate analyses were used to
analyze the hazard of death within 30 days from SAB.
Results: A total of 16 330 cases of SAB were identified: 57% were hospital-associated (HA), 31% were
community-acquired (CA) and 13% were of undetermined acquisition. The overall adjusted incidence rate remained
stable at 23 per 100 000 population but the proportion of SAB cases older than 75 years increased significantly.
Comorbidity in the cohort as measured by Charlson comorbidity index (CCI) score and alcohol-related diagnoses
increased over the study period. In contrast, among the population controls the CCI remained stable and
alcohol-related diagnoses increased slightly. For HA SAB crude 30-day mortality decreased from 27.8% to 21.8%
(22% reduction) whereas the change for CA SAB was small (26.5% to 25.8%). By multivariate Cox regression, age,
female sex, time period, CCI score and alcohol-related diagnoses were associated with increased mortality
regardless of mode of acquisition.
Conclusions: Throughout a 14-year period the overall incidence of SAB remained stable while the overall short
term prognosis continued to improve despite increased age and accumulation of comorbidity in the cohort.
However, age and comorbidity were strong prognostic indicators for short term mortality.
Keywords: Bacteraemia, Epidemiology, Incidence, Mortality, Comorbidity, Alcoholism, Staphylococcus aureus,
Charlson comorbidity index
Background
During the last decades general improvements in
health and socioeconomic conditions in many indus-
trialized countries have led to an older population [1].
In Denmark, individuals older than 65 years increased
only modestly from 16% to 18% between 1990 and
2010 but the proportion of individuals older than 90
increased by 72% [2]. Age is one of the strongest
determinants of risk of infectious disease [3]. Older
age is further associated with an increased risk and
prevalence of comorbidity [4]. The combination of an
ageing population and associated comorbidity may lead
to an increase in the incidence of sepsis and blood-
stream infection. This was evident throughout the
1980’s and 1990’s for Staphylococcus aureus bacteraemia
(SAB) and bacteraemia in general as shown by us and
others [5-7]. During the same time frame, the prevalence
of several other risk factors has increased. These include
increased use of cancer chemotherapy, immunosuppres-
sive therapy, intravascular devices, and invasive medical
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and surgical procedures. Taken together ageing, accumula-
tion of comorbidity and other risk factors may influence
both the incidence and prognosis of SAB.
Although much attention has been drawn towards
methicillin-resistant S. aureus (MRSA) in recent years,
methicillin-susceptible S. aureus (MSSA) continues to
constitute the most common type of SAB in most parts
of the world. In Denmark MRSA SAB is infrequent.
Using a nationwide cohort we investigated contemporary
changes in the incidence rate (IR) of SAB (> 99%
MSSA), temporal changes in age and underlying mor-
bidity and assessed the effect of each on short term out-
come from MSSA SAB from 1995 to 2008.
Methods
Study population
The register-based matched cohort was created by mer-
ging data from four national registries based on the
unique civil registration number assigned to each Danish
citizen [8]. The study was approved by the Ethics Com-
mittee for the Municipalities of Copenhagen and Freder-
iksberg (01–369 ⁄ 93) and the Danish Data Protection
Agency (2009-41-4179).
The Danish Staphylococcal Bacteraemia Study Group
has carried out a continuous, nationwide registration of
SAB in Denmark since 1956 [6,9]. The present study
defined a case as an individual with a first episode of SAB
identified via the registry between January 1, 1995 and
December 31, 2008. Discharge records for each admission
with SAB were reviewed [6,9]. We defined hospital-
associated SAB (HA SAB) as an infection acquired after
48 hours of hospitalisation, an infection in a patient in
ambulatory care in a specialized hospital department, or a
case residing in a nursing home. Community-acquired
SAB (CA SAB) was defined as an infection present at the
time of hospitalization in patients not meeting the defin-
ition of HA SAB. Methicillin resistance was determined
by antimicrobial susceptibility testing and confirmed by
the presence of the mecA gene [10,11].
Information on the number of persons alive in Den-
mark on January 1 from 1995 through 2008 was obtained
from Statistics Denmark (Danmarks Statistik at http://
www.dst.dk). These included total number and sub-
groups defined by age and gender.
The Danish Civil Registration System which is updated
daily, tracks changes in vital status and migration for the
entire Danish population [8]. For each case, we ran-
domly selected 10 control subjects, matched by age (year
of birth) and sex. We used the risk set sampling tech-
nique (i.e. eligible control subjects had to be alive and at
risk of a first hospitalization with SAB on the date the
corresponding case was admitted [12]).
Data on comorbidity was collected from the National
Patient Registry. This registry is updated monthly and
holds information on all hospital admissions and dis-
charge diagnoses of all patients treated in a Danish hos-
pital since January 1, 1977 as well as all outpatient
contacts since January 1, 1995. The International Classi-
fication of Diseases (ICD)-8 was used from 1977 through
1993; and ICD-10 from 1994. Comorbidity prior to the
SAB admission was assessed by estimating the Charlson
comorbidity index (CCI) score [13,14]. Briefly, the CCI
is a validated score system used to asses patients’ comor-
bid conditions in longitudinal studies [15], and takes into
account both the number and severity of comorbid dis-
ease. We calculated the CCI score for cases and controls
by gathering diagnoses from the National Patient Regis-
try from up to 10 years prior to the SAB index date and
excluding diagnoses from the admission with SAB. To
avoid the influence of re-registration of diagnoses, each
of the 17 Charlson diagnostic categories could only con-
tribute one time to the overall index. We defined three
levels of comorbidity for categorizing patients in this
study: none (patients without underlying disease), inter-
mediate (weighted index of comorbidity CCI 1–2) and
high (CCI ≥ 3). Alcohol related comorbidity is not
included in the CCI score and was assessed separately as
previously described [16,17]. We considered the follow-
ing diagnosis codes: for ICD-10 classification: F10,
G31.2, G62.1, G72.1, I42.6, K29.2, K86.0, K70, R78.0,
T51, Z72.1, and for ICD-8 classification: 291 (Alcoholic
psychosis), 303 (Alcoholism), 979 (Alcohol in combin-
ation with specified medicinal agents), 980 (Toxic effect
of alcohol), 577.10 (Chronic pancreatitis due to alcohol),
571.09 (Cirrhosis of the liver due to alcohol), 571.10
(Steatosis of the liver due to alcohol). ICD-10 K70
(cirrhosis) is included in the CCI score but was only
assessed for alcohol-related conditions.
Statistics
Annual data were divided into five periods (1995–1997,
1998–2000, 2001–2003, 2004–2006 and 2007–2008) for
the assessment of temporal changes, and age was divided
into 6 groups (<1, 1–15, 16–35, 36–55, 56–75, >75).
Using the cumulative incidence proportion method to
calculate incidence rates, that assumes that all indivi-
duals of a given birth cohort remain alive for a given
year, indicated that incidence rates increased over time.
However, annual survival rates for individuals older than
65 improved significantly during the study, leading to an
average increase in days at risk of SAB in the older age
strata in more recent time periods. E.g. among popula-
tion controls >75 years the 30-day- and 1-year mortality
proportion decreased from 7,0% and 51,4% in 1995–
1997 to 1,2% and 12,8% in 2007–2008, respectively.
Therefore, we adjusted the number of days at risk in
each gender- and age stratum by a correction factor
derived from annual survival among the population
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controls. Incidence rates with 95% CIs were calculated
based on these adjusted data. Categorical variables were
compared by chi-square test. Ninety days survival curves
were constructed by the Kaplan-Meier method, and the
proportional hazards assumption was evaluated visually
on survival plots. Mortality rate ratios with 95% CIs
were calculated using Cox proportional hazards models.
Unvariate and multivariate Cox regression was per-
formed to determine the mortality rate ratios within 30
days of SAB. All variables in the multivariate analysis
were analysed using the forced entry procedure. Ana-
lyses were performed using PASW v.18 (SPSS Inc.,
Chicago, IL, USA).
Results
During the study period, 17 450 individuals were hospi-
talized with a first episode of SAB. A total of 820 of
these were excluded due to a temporary or invalid per-
sonal identifier (n=652), negative follow up time
(n=142), no sample date (n=18) or a duplicated person
identifier (n=8). MRSA was rare (<1%, Table 1).
Characteristics of cases and controls
Fifty-seven percent of cases were HA and 31% were CA.
In 13% of cases the place of acquisition could not be
determined. The characteristics of HA and CA cases are
shown in Table 1. Overall, patients were in their mid-
sixties and the majority were male.
The proportion of cases older than 75 years increased
from 23.2% in 1995–1997 to 29.8% in 2007–2008 (p =
0.0001), and the proportion of cases aged 1–55 years
decreased during the same period from 37.1% to 28.1%
(p = 0.0001). The proportion of cases aged <1 years and
56–75 years were stable.
The proportion of cases who had a CCI score > 0
increased during the study period from 60.8% in 1995–
1997 to 69.5% in 2007–2008 (p = 0.0001), of which the
proportion of individuals with a CCI score > 2 increased
from 19% to 32% (p = 0.0001). The proportion of cases
with a CCI score increased with age although fewer cases
older than 75 years compared to the 56–75 year old
stratum had a CCI score greater than 0 (72.0% vs. 74.8%,
p = 0.001). Patients with HA SAB had higher CCI scores
than CA SAB. Among HA SAB 70,0% had a CCI greater
than 0 compared to 54,8% among CA SAB (p = 0.0001).
The proportion of cases with pre-admission alcohol-
related diagnoses increased from 7% to 12% between
1995–1997 and 2007–2008 (p = 0.0001). Alcohol-related
diagnoses were more frequent among CA SAB com-
pared to HA SAB (p = 0.0001).
The distribution of CCI (p = 0.0001) and alcohol-related
disorders (p = 0.0001) among the age- and sex matched
controls differed from cases. For controls 23% had a CCI
score of 1–2 and only 6.0% had a CCI score > 2. Over time
the proportion of controls with a CCI score > 0 decreased
from 31.4% in 1995–1997 to 28.0% in 2007–2008 (p =
0.0001), while the proportion of controls with pre-
admission alcohol-related diagnoses increased from 1.5%
to 2.1% (p = 0.0001).
Incidence rates of SAB
The adjusted overall IR (22.7/100 000 population (95%
CI: 22.4-23.1/100 000)) of first time SAB remained con-
stant from 1995 to 2008 (Table 2). IRs increased with
age and were higher among males (27.9/100.000 popula-
tion (95%CI: 27.4-28.5/100 000)) than females (17.6/
100.000 population (95%CI: 17.2-18.1/100.000)). The IRs
decreased slightly from 1995 to 2008 among persons
Table 1 Characteristics of cases with hospital-associated
and community-acquired Staphylococcus aureus
bacteraemia in Denmark from 1995-2008
Hospital-associated
SAB N = 9412 (56.6%)
Community-acquired




























SAB: Staphylococcus aureus bacteraemia; MRSA: Methicillin-resistant
Staphylococcus aureus.
CCI: Charlson comorbidity index.
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aged 1–75 years and were stable among cases aged <1
and >75 years (Table 2).
Mortality
The overall cumulative mortality among cases within 30
days from SAB was 25.7%. The median survival of HA,
CA and undetermined acquisition SAB was 556 days
(501–610), 836 days (721–951) and 476 days (386–566),
respectively.
There was a significant impact of origin, age, gender,
CCI, alcohol-related disorders and time period on mor-
tality (Tables 3 and 4). Due to few deaths among SAB
patients <36 years the periodic 30 day mortality propor-
tions in these age groups were not presented. The high-
est impact on mortality was noted with age (Figure 1).
The impact diminished in multivariate analyses, but
remained the most influential. Second and third highest
impact was seen with alcohol-related disorders and
comorbidity assessed by CCI (Figure 2). By multivariate
analyses the impact of alcohol-related disorders
increased after adjustment for age whereas the impact of
CCI decreased. This was seen among both HA and CA
SAB. Multivariate analyses showed improved survival
over time particularly among cases of HA but also CA
bacteraemia. Gender had the lowest impact on mortality
and men had lower mortality in the adjusted analysis.
Discussion
In a cohort of more than 16 000 individual episodes of
SAB, we show that the incidence of first time SAB
remained stable across age groups, origin and degree of
comorbidity from 1995 to 2008 after several decades of
increasing incidence rates. Further, we document that
overall short term survival rates continued to improve
although mortality rates were higher with increasing age
and level of comorbidity.
Table 2 Incidence rates* of Staphylococcus aureus bacteraemia in Denmark from 1995-2008
Year 1995-1997 1998-2000 2001-2003 2004-2006 2007-2008
All 23.4(22.6-24.2) 23.5(22.8-24.3) 21.2(20.5-21.9) 23.4(22.6-24.1) 21.8(20.9-22.7)
Sex
Male 28.3(27.1-29.5) 29.4(28.2-30.6) 26.1(25.0-27.2) 28.6(27.5-29.8) 27.1(25.8-28.6)
Female 18.7(17.8-19.7) 17.9(17.0-18.8) 16.5(15.6-17.4) 18.2(17.3-19.1) 16.6(15.5-17.7)
Age, years
< 1 40.5(31.8-49.2) 37.1(28.7-45.6) 42.3(33.2-51.4) 57.0(46.3-67.6) 52.6(40.1-65.1)
1-15 5.3(4.4-6.1) 4.6(3.8-5.4) 3.1(2.5-3.7) 3.4(2.8-4.1) 3.5(2.7-4.4)
16-35 7.3(6.5-8.1) 6.9(6.1-7.6) 4.3(3.6-4.9) 4.3(3.7-4.9) 4.0(3.2-4.7)
36-55 16.8(15.6-18.1) 15.7(14.5-16.8) 13.4(12.3-14.4) 13.7(12.6-14.8) 13.5(12.2-14.8)
56-75 58.9(55.8-62.0) 51.6(48.9-54.3) 45.3(42.9-47.7) 46.7(44.3-49.0) 43.5(40.8-46.2)
> 75 114.2(106.3-122.0) 120.7(113.4-128.1) 112.7(105.9-119.5) 126.7(119.6-133.8) 107.7(99.7-115.6)
* Adjusted incidence rates per 100 000 population years, (): 95% Confidence interval.
Table 3 Thirty-day mortality proportions from Staphylococcus aureus bacteraemia in Denmark between 1995 and 2008
Year 1995-1997 1998-2000 2001-2003 2004-2006 2007-2008
All 0.27(0.25-0.28) 0.26(0.25-0.28) 0.26(0.24-0.27) 0.26(0.25-0.27) 0.23(0.21-0.25)
Sex
Female 0.29(0.26-0.31) 0.27(0.25-0.30) 0.28(0.26-0.30) 0.28(0.25-0.30) 0.25(0.22-0.28)
Male 0.26(0.24-0.28) 0.25(0.24-0.27) 0.24(0.22-0.26) 0.25(0.23-0.27) 0.22(0.20-0.24)
Age, years
36-55 0.19(0.17-0.22) 0.17(0.14-0.19) 0.15(0.12-0.18) 0.15(0.12-0.17) 0.11(0.08-0.14)
56-75 0.29(0.27-0.32) 0.26(0.24-0.28) 0.23(0.21-0.25) 0.24(0.22-0.26) 0.23(0.21-0.26)
> 75 0.45(0.42-0.48) 0.44(0.41-0.47) 0.42(0.39-0.45) 0.42(0.39-0.45) 0.37(0.33-0.40)
CCI
0 0.20(0.18-0.22) 0.20(0.18-0.23) 0.18(0.15-0.20) 0.16(0.14-0.18) 0.17(0.15-0.20)
1-2 0.30(0.28-0.32) 0.29(0.27-0.31) 0.29(0.26-0.31) 0.27(0.25-0.30) 0.25(0.22-0.28)
> 2 0.34(0.31-0.38) 0.30(0.27-0.33) 0.30(0.27-0.33) 0.34(0.31-0.36) 0.26(0.23-0.29)
Alcohol-related disorders 0.34(0.28-0.40) 0.32(0.27-0.37) 0.31(0.26-0.35) 0.32(0.27-0.37) 0.30(0.24-0.35)
CCI: Charlson comorbidity index, (): 95% Confidence interval.
Mejer et al. BMC Infectious Diseases 2012, 12:260 Page 4 of 7
http://www.biomedcentral.com/1471-2334/12/260
The stable incidence of SAB in the observation period
was also found elsewhere [18], but is somewhat surpris-
ing. A continued increase in incidence was expected
given an increasing larger proportion of elderly with
more comorbidity and in a time with more chemother-
apy, immunosuppressive treatment and increased use of
invasive procedures and devices. A possible explanation
may be that although the proportion of elderly is
expanding, the elderly are ageing healthier than just a
decade ago. Our analysis of the control population cer-
tainly showed a considerable improvement in survival
over time in support of this.
This study identified high risk of SAB among persons
< 1 year. This finding is consistent with other contem-
porary studies [19-21] and warrants further studies on
SAB among neonates.
The short term mortality associated with SAB
decreased by 14% from 1995–1997 to 2007–2008 in
spite of the presence of more comorbidity and increased
age. In fact, the total number of deaths attributed to
SAB declined for the first time since 2000 because the
incidence rate also remained stable. We speculate that
the improved gains may have been accomplished
through healthier ageing and improved treatment of
comorbid diseases, but many factors may be at play.
Still, further improvement in the treatment of SAB must
be accomplished if the improvement in the prognoses of
SAB is to follow the improvement seen in the age-
matched general population.
The strengths of this study lies in its size, the longitu-
dinal and population-based design, the low frequency of
MRSA which enabled a clean focus on MSSA, the uni-
form registration system, and the inclusion of randomly
selected age- and sex matched population controls that
allowed for adjustment of a baseline mortality risk.
There are also potential limitations. First, the discharge
data, which the assessment of comorbidity was built
upon, may have contained errors, but this misclassifica-
tion bias would be non-differential between cases and
controls. Second, the temporal rise in CCI and alcohol-
Table 4 Multivariate analysis of factors associated with mortality among cases of hospital-associated and community-
acquired Staphylococcus aureus bacteraemia in Denmark from 1995-2008
Hospital-associated SAB Community-acquired SAB
30-d mortality (%) Adjusted MRR (95% CI) 30-d mortality (%) Adjusted MRR (95% CI)
Overall 2368/9412 (25.2%) 1439/5074 (28.4%)
Age, years
1 > 19/337 (5.6%) 0.45 (0.28-0.73) 1/58 (1.7%) 0.13 (0.02-0.93)
1-15 9/232 (3.9%) 0.27 (0.14-0.53) 1/235 (0.4%) 0.03 (0.04-0.23)
16-35 32/535 (6.0%) 0.39 (0.27-0.56) 15/405 (3.7%) 0.25 (0.14-0.42)
36-55 282/1733 (16.3%) 1.0 152/938 (16.2%) 1.0
56-75 983/3982 (24.7%) 1.7 (1.5-1.9) 483/1734 (27.9%) 1.8 (1.5-2.2)
> 75 1043/2593 (40.2%) 3.2 (2.8-3.7) 787/1704 (46.2%) 3.6 (3.0-4.4)
Sex
Female 988/3755 (26.3%) 1.0 616/1927 (32.0%) 1.0
Male 1380/5657 (24.4%) 0.90 (0.83-0.98) 823/3147 (26.2%) 0.82 (0.74-0.92)
CCI score
0 527/2822 (18.7%) 1.0 435/2293 (19.0%) 1.0
1-2 1049/3868 (27.1%) 1.3 (1.1-1.4) 606/1801 (33.6%) 1.3 (1.1-1.5)
> 2 792/2722 (29.1%) 1.4 (1.2-1.6) 398/980 (40.6%) 1.6 (1.4-1.9)
Alcohol-related disorders
No 2113/8585 (24.6%) 1.0 1251/4532 (27.6%) 1.0
Yes 255/827 (30.8%) 1.7(1.5-2.0) 188/542 (34.7%) 1.9(1.6-2.2)
Year
1995-1997 526/1893 (27.8%) 1.0 262/989 (26.5%) 1.0
1998-2000 502/1992 (25.2%) 0.83 (0.74-0.94) 365/1261 (28.9%) 1.00 (0.85-1.17)
2001-2003 512/2010 (25.5%) 0.79 (0.70-0.89) 257/893 (28.8%) 0.89 (0.75-1.06)
2004-2006 535/2171 (24.6%) 0.74 (0.66-0.84) 355/1155 (30.7%) 0.90 (0.76-1.05)
2007-2008 293/1346 (21.8%) 0.65 (0.56-0.75) 200/776 (25.8%) 0.74 (0.61-0.89)
SAB: Staphylococcus aureus bacteraemia; MRR: Mortality rate ratio; CI: confidence interval, CCI: Charlson comorbidity index.
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related diagnoses among cases could have been caused
by an intensified registration of diagnoses. This is, how-
ever, unlikely since diagnoses included in the CCI score
among population controls remained constant. Third,
using CCI as a aggregated estimate of comorbidity has
limitations: the CCI unlikely included all comorbid dis-
eases and the improved prognosis of many diseases in-
cluding cancer and HIV/AIDS in the study period may
have overadjusted the impact of CCI on mortality late in
the observation period compared to early. Fourth, sur-
veillance bias among the increasing proportion of cases
with pre-SAB comorbidity could explain part of the
improved prognosis of SAB.
Fifth, a potential major limitation of the study, is its
classification of HA and CA SAB. The present study
included community onset healthcare-related SAB as
























Figure 2 Survival curves of 16630 cases with Staphylococcus aureus bacteraemia between 1995 and 2008 according to Charlson
comorbidity index score.


























Figure 1 Survival curves of 16630 cases with Staphylococcus aureus bacteraemia between 1995 and 2008 according to age.
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HA SAB which could make comparison to data from
the recent literature difficult.
Conclusion
In conclusion, the overall IR of first time SAB did not
increase from 1995 to 2008 as would be expected from
the changing epidemiological profile of the Danish
population and the increased medical activity. Further,
the short term prognosis of SAB improved; especially
among HA SAB. Although the over-all risk of dying
from SAB declined, the short term mortality of SAB is
still high, especially among the old and comorbid, which
continues to constitute a growing proportion of the Da-
nish SAB patients. This study underscores the import-
ance of adjustment for age and comorbidity when
comparing risk of and mortality from SAB sequentially
or between countries. In addition, it highlights the po-
tential benefits of future studies in prevention and treat-
ment of SAB among the old and comorbid patients.
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